China's NMPA clears clinical trials for LNK-01004 for atopic dermatitis
Aug. 4, 2022
Lynk Pharmaceuticals' LNK-01004 has been cleared by China's National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis.
